Clinical Trial Update: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of adding dapagliflozin to extended-release metformin versus metformin XR alone in HR+, HER2-, advanced breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Dapagliflozin (dapagliflozin)
• Fulvestrant (fulvestrant)
• metformin XR (metformin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-12-12